EUCTR2008-001823-71-IT
Active, not recruiting
Not Applicable
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-cam
Associazione Malattie Sangue ONLUS0 sitesMay 20, 2008
ConditionsCLL patientsMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemia
Drugslenalidomide
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- CLL patients
- Sponsor
- Associazione Malattie Sangue ONLUS
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- signed written informed consent
- •\- age 18 years or older
- •\- WHO performance status 0\-II
- •\- life expectancy \> 6 months
- •\- confirmation BCLL
- •\- no major infection
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •\- any serious medical condition or psychiatric illness
- •\- pregnant or lactating women
- •\- active secondary malignancy
- •\- negativity for CD52 marker
- •\- previous autologous or allogeneic stem cell transplant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
Terminated
Phase 1
A Phase Ib study of lenalidomide in combination with imatinib for adult patients with chronic myeloid leukaemia in second molecular remissioACTRN12615001169538South Australian Health & Medical Research Institute (SAHMRI)3
Active, not recruiting
Not Applicable
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Active, not recruiting
Phase 1
PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA - NDHistological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, c. nodal marginal zone lymphoma d. splenic marginal zone lymphomae. e. extranodal non-gastric marginal zone lymphomaMedDRA version: 9.1Level: LLTClassification code 10029463MedDRA version: 9.1Level: LLTClassification code 10003911MedDRA version: 9.1Level: LLTClassification code 10041652MedDRA version: 9.1Level: LLTClassification code 10025345EUCTR2008-001591-80-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
Active, not recruiting
Phase 1
Phase II Study of the Adjunctive Use of Lenalidomide in Patients Undergoing Reduced Intensity Conditioning Allogeneic Transplantation for Multiple Myeloma - Post Transplant Lenalidomide for Multiple Myeloma (Version 1)Multiple MyelomaMedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2009-012033-30-GBniversity Hospitals Birmingham NHS Foundation Trust40